多西紫杉醇联合卡铂治疗晚期非小细胞肺癌的疗效观察

Clinical observation of combination of chemotherapy with docetaxel and carboplation in the treatment of advanced non-small cell lung cancer

目的观察多西紫杉醇联合卡铂治疗晚期非小细胞肺癌近期疗效及毒副反应。方法47例晚期非小细胞肺癌住院患者给予多西紫杉醇联合卡铂治疗,多西紫杉醇75mg/m2,静滴,d1,卡铂根据AUC5计算用量,静滴,d1,21d为1周期,每个患者均完成2个周期以上,评价疗效和不良反应,并随访生存期。结果47例患者治疗后CR0例、PR24例、NC17例、PD6例,有效率为51.1%。KS评分增加者70.2%(33/47)、稳定21.3%(10/47)、下降8.5%(4/47)。中位生存期9个月(95%CI8～10个月),1年生存率27.1%。最常见的毒副反应为骨髓抑制,全组68.1%(32/47)出现白细胞下降,其中Ⅲ度～Ⅳ度白细胞减少发生率为25.5%,恶心、呕吐29.8%(14/47),脱发87.2%(41/47)。其余毒副反应轻微,均可耐受。结论多西紫杉醇联合卡铂治疗晚期非小细胞肺癌有较好的疗效,毒副反应比较轻微。

Objective To investigate effect and safety of combination of chemotherapy with docetaxel and carboplatin in the treatment of advanced non-small cell lung cancer. Methods 47 patients with advanced non-small cell lung cancer received docetaxel 75 mg/ m2 on day 1 and carboplatin according AUC 5 on day 1 every 3 weeks,and each patient should complete no less than two cycles. The response and toxicity of chemotherapy was evaluated and survival rate was followed up. Results In the 47 valuable cases, partial response （PR）was observed in 24 cases, no change（ NC ）was in 17 cases, progress disease was（PD） in 6 cases, and overall response rate was 51.1%. Kamofsky（KS） raised rate was 70.2% （ 33/47 ） , Median survival time was 9 month （95% CI 8 - 10 month） and 1 year survival rate was 27. 1%. The toxicity including 25.5 % grade 3 -4 leucopenia,29. 8 % nausea and vomiting, and 87. 2% loss of hair. Conclusion Combination of chemotherapy with docetaxel and carboplatin is effective and safe in treatment of advanced non-small cell lung cancer.